Amgen to terminate participation in co-development and commercialization of brodalumab
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Amgen (AMGN) Announces Termination of Brodalumab Agreement with AstraZeneca (AZN)
May 26, 2015 6:56 AM EDTAmgen (NASDAQ: AMGN) announced the Company has commenced termination of its participation in the co-development and commercialization of brodalumab with AstraZeneca (NYSE: AZN). Brodalumab, an investigational IL-17 inhibitor, is in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and... More



